Last 23 quarters of trend data · Healthcare · Medical - Diagnostics & Research
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -8.47 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 35.87 | — | — | 15.07 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 4.18 | 1.78 | 2.28 | 1.73 | 1.96 | 1.60 | 0.74 | 1.76 | 1.64 | 3.04 | 1.93 | 3.39 | 4.38 | 5.43 | 7.69 | 1.10 | 15.48 | 11.98 | 1.18 | 1.65 | 1.46 |
| — | +11.2% | +209.9% | -1.7% | +19.9% | -47.6% | -61.8% | -48.2% | -62.7% | -44.0% | -74.9% | +207.6% | -71.7% | -54.7% | +553.4% | -33.0% | +961.2% | — | — | — | — | |
| P/B Ratio | 1.83 | 3.55 | 2.71 | 1.45 | 1.15 | 0.75 | 0.32 | 0.43 | 0.28 | 0.38 | 0.24 | 0.34 | 0.37 | 0.64 | 0.65 | 0.95 | 1.28 | 0.92 | — | — | 1.42 |
| — | +375.0% | +757.0% | +236.5% | +305.7% | +97.5% | +29.7% | +26.2% | -24.4% | -41.0% | -62.4% | -64.1% | -70.9% | -29.8% | — | — | -9.9% | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 17.41 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 4.71 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 52.8% | 65.0% | 64.8% | 59.5% | 59.5% | 41.2% | 42.4% | 37.2% | 50.8% | 63.4% | 59.0% | 49.2% | 33.9% | 46.8% | 29.6% | 51.6% | 44.9% | 32.5% | 39.2% | 36.7% | 34.5% |
| — | +57.6% | +52.7% | +59.9% | +17.3% | -35.0% | -28.1% | -24.4% | +49.7% | +35.4% | +99.4% | -4.7% | -24.4% | +44.0% | -24.5% | +40.5% | +30.2% | -25.9% | +2.6% | +17.5% | — | |
| Operating Margin | -41.3% | -47.1% | -27.0% | -33.9% | -26.2% | -56.9% | -61.4% | -158.0% | -151.8% | -178.6% | -142.8% | -217.2% | -265.3% | -228.1% | -302.4% | 8.8% | -396.2% | -544.7% | -0.6% | -47.5% | -7.2% |
| — | +17.2% | +56.0% | +78.5% | +82.8% | +68.1% | +57.0% | +27.3% | +42.8% | +21.7% | +52.8% | -2554.6% | +33.0% | +58.1% | -50447.1% | +118.6% | -5439.2% | -3004.7% | -103.1% | -330.0% | — | |
| Net Margin | -40.8% | -19.3% | -64.3% | -76.9% | -31.4% | -70.2% | -60.0% | -155.8% | -137.2% | -180.5% | -133.6% | -321.1% | -278.1% | -334.9% | -211.2% | 3.1% | -346.8% | -3446.3% | -35.8% | -132.5% | -107.7% |
| — | +72.5% | -7.1% | +50.6% | +77.1% | +61.1% | +55.1% | +51.5% | +50.7% | +46.1% | +36.7% | -10550.0% | +19.8% | +90.3% | -489.3% | +102.3% | -222.0% | -27768.5% | -1174.1% | -515.3% | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -21.8% | -8.4% | -15.6% | -16.7% | -4.7% | -8.0% | -6.3% | -9.3% | -5.8% | -5.4% | -4.2% | -7.7% | -6.0% | -9.6% | -4.4% | 0.7% | -7.0% | -65.8% | — | — | -310.7% |
| — | -5.6% | -150.2% | -80.1% | +17.5% | -46.1% | -50.6% | -20.4% | +4.8% | +43.3% | +4.8% | -1182.3% | +13.5% | +85.4% | — | — | +97.8% | — | — | — | — | |
| ROA | -18.1% | -5.5% | -12.2% | -14.1% | -3.7% | -6.2% | -5.0% | -7.3% | -4.6% | -4.5% | -3.4% | -6.4% | -4.9% | -7.6% | -3.4% | 0.6% | -5.4% | -64.4% | -20.7% | -35.1% | -32.9% |
| — | +11.3% | -145.1% | -93.3% | +17.7% | -36.9% | -44.5% | -13.9% | +6.6% | +41.0% | +0.2% | -1255.6% | +10.4% | +88.2% | +83.4% | +101.6% | +83.4% | -723.2% | -1072.5% | -371.2% | — | |
| ROIC | -21.2% | -32.9% | -6.9% | -6.3% | -3.2% | -5.9% | -6.6% | -8.9% | -5.8% | -5.3% | -4.3% | -5.2% | -9.2% | -18.2% | -12.6% | 3.9% | -14.5% | -17.3% | — | -5.8% | -1.0% |
| — | -454.2% | -5.7% | +29.0% | +44.1% | -12.6% | -51.2% | -70.4% | +37.0% | +71.0% | +65.6% | -235.3% | +37.0% | -4.9% | — | +166.5% | -1367.3% | -194.0% | — | +13.6% | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 | 0.02 | 0.03 | 0.03 | 0.04 | 0.01 | 0.01 | 0.01 | 0.02 | 0.03 | 0.03 | 0.03 | 0.07 | 0.06 | — | — | 1.42 |
| — | -57.0% | -88.2% | -62.5% | -63.8% | +37.8% | +270.6% | +198.8% | +56.8% | -54.8% | -68.6% | -58.7% | -66.2% | -57.6% | — | — | -95.2% | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 1.38 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 3.01 | 4.04 | 5.15 | 3.01 | 1.51 | 2.16 | 2.07 | 2.36 | 1.40 | 2.06 | 2.33 | 2.37 | 2.40 | 3.96 | 4.59 | 4.23 | 5.05 | 4.89 | 1.73 | 1.82 | 0.41 |
| — | +87.2% | +148.9% | +27.9% | +8.0% | +5.0% | -11.0% | -0.6% | -41.7% | -48.1% | -49.3% | -43.9% | -52.4% | -19.1% | +165.3% | +132.3% | +1122.7% | +97.8% | +76.9% | +94.9% | — | |
| Quick Ratio | 2.76 | 3.66 | 4.60 | 2.76 | 1.30 | 2.06 | 1.89 | 2.18 | 1.22 | 1.98 | 2.25 | 2.29 | 2.32 | 3.89 | 4.52 | 4.15 | 4.88 | 4.65 | 1.52 | 1.70 | 0.41 |
| — | +77.2% | +142.7% | +26.7% | +6.8% | +4.2% | -15.8% | -5.0% | -47.4% | -49.0% | -50.2% | -44.7% | -52.5% | -16.5% | +197.9% | +143.5% | +1082.5% | +95.5% | +69.7% | +103.2% | — | |
| Interest Coverage | -149.26 | -1686.08 | -1078.44 | -629.46 | -122.25 | -167.52 | -159.48 | -316.55 | -149.38 | -404.06 | -580.94 | — | -337.04 | -444.80 | -313.47 | -6.15 | -170.01 | -78.69 | -11.57 | -34.37 | -32.82 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 23 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PRE stock.
Prenetics Global Limited's current P/E is -8.5x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Prenetics Global Limited's current operating margin is -41.3%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Prenetics Global Limited's business trajectory between earnings reports.